Company / Return on Equity (ROE)
BioNexus Gene Lab Corp Return on Equity (ROE) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-34.6%
FY2025
5-year range
-34.6% / 10.5%
FY2021-FY2025
Trend
-80.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
BioNexus Gene Lab Corp reports negative total equity of -34.6% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-34.6% in FY2025 with a 5-year CAGR of -51.1%.
Declined from -27.2% to -34.6% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -29.3pp
- 5-Year Change
- -51.1pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 80.4% year-over-year.
- Peak return on equity (roe) was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -34.6% | -80.4% |
| FY2024 | -19.2% | +29.5% |
| FY2023 | -27.2% | -409.7% |
| FY2022 | -5.3% | -151.0% |
| FY2021 | 10.5% | -36.2% |
| FY2020 | 16.4% | +174.8% |
| FY2019 | -22.0% | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026